<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36528708</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2024</Year><Month>06</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1476-5551</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Leukemia</Title><ISOAbbreviation>Leukemia</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors.</ArticleTitle><Pagination><StartPage>244</StartPage><EndPage>247</EndPage><MedlinePgn>244-247</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41375-022-01787-8</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Milojkovic</LastName><ForeName>Dragana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Reynolds</LastName><ForeName>Catherine J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Sandoval</LastName><ForeName>Diana M&#x16b;noz</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-8350-3989</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pieper</LastName><ForeName>Franziska P</ForeName><Initials>FP</Initials><Identifier Source="ORCID">0000-0002-4857-0518</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Siyi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pade</LastName><ForeName>Corinna</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gibbons</LastName><ForeName>Joseph M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKnight</LastName><ForeName>&#xc1;ine</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loaiza</LastName><ForeName>Sandra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Imperial College NHS Healthcare Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palanicawander</LastName><ForeName>Renuka</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Imperial College NHS Healthcare Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Innes</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Imperial College NHS Healthcare Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Claudiani</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Imperial College NHS Healthcare Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apperley</LastName><ForeName>Jane F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Altmann</LastName><ForeName>Daniel M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Immunology and Inflammation, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyton</LastName><ForeName>Rosemary J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-5608-0797</Identifier><AffiliationInfo><Affiliation>Department of Infectious Disease, Imperial College London, London, UK. r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lung Division, Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK. r.boyton@imperial.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21011</GrantID><Acronym>LLR_</Acronym><Agency>Blood Cancer UK</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/W020610/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Leukemia</MedlineTA><NlmUniqueID>8704895</NlmUniqueID><ISSNLinking>0887-6924</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000092004">Tyrosine Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>8A1O1M485B</RegistryNumber><NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092004" MajorTopicYN="N">Tyrosine Kinase Inhibitors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015464" MajorTopicYN="Y">Leukemia, Myelogenous, Chronic, BCR-ABL Positive</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>RJB and DMA are members of the Global T cell Expert Consortium and have consulted for Oxford Immunotec outside the submitted work. DMA has received payment as a member of the AstraZeneca Long Covid Advisory Board and the Pfizer COVID-19 digital toolkit development. DM has received honoraria from Novartis, BMS, Incyte and Pfizer outside the submitted work. JFA has received research funding from Novartis and Pfizer and honoraria from Incyte outside the submitted work. DM received research funding from Incyte for the submitted work. Otherwise, the authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>17</Day><Hour>23</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>12</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36528708</ArticleId><ArticleId IdType="pmc">PMC9758679</ArticleId><ArticleId IdType="doi">10.1038/s41375-022-01787-8</ArticleId><ArticleId IdType="pii">10.1038/s41375-022-01787-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee CY, Shah MK, Hoyas D, Solovyov A, Douglas M, Taur Y, et al. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Disco. 2022;12:62&#x2013;73. doi: 10.1158/2159-8290.CD-21-1033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/2159-8290.CD-21-1033</ArticleId><ArticleId IdType="pmc">PMC8758535</ArticleId><ArticleId IdType="pubmed">34753749</ArticleId></ArticleIdList></Reference><Reference><Citation>Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M, et al. COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol. 2022;196:559&#x2013;65. doi: 10.1111/bjh.17890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17890</ArticleId><ArticleId IdType="pmc">PMC8652631</ArticleId><ArticleId IdType="pubmed">34636033</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lavallade H, Khoder A, Hart M, Sarvaria A, Sekine T, Alsuliman A, et al. Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signalling. Blood. 2013;122:227&#x2013;38. doi: 10.1182/blood-2012-11-465039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-11-465039</ArticleId><ArticleId IdType="pmc">PMC5726329</ArticleId><ArticleId IdType="pubmed">23719297</ArticleId></ArticleIdList></Reference><Reference><Citation>Arcani R, Colle J, Cauchois R, Koubi M, Jarrot PA, Jean R, et al. Clinical characteristics and outcomes of patients with haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an important issue. Ann Hematol. 2021;100:2799&#x2013;803. doi: 10.1007/s00277-021-04656-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-021-04656-z</ArticleId><ArticleId IdType="pmc">PMC8437431</ArticleId><ArticleId IdType="pubmed">34518918</ArticleId></ArticleIdList></Reference><Reference><Citation>Claudiani S, Apperley JF, Parker EL, Marchesin F, Katsanovskaja K, Palanicawandar R, et al. Durable humoral responses after the second anti-SARS-CoV-2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors. Br J Haematol. 2022;197:e1&#x2013;4. doi: 10.1111/bjh.18001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.18001</ArticleId><ArticleId IdType="pubmed">34923623</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrington P, Doores KJ, Radia D, O&#x2019;Reilly A, Lam HPJ, Seow J, et al. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. Br J Haematol. 2021;194:999&#x2013;1006. doi: 10.1111/bjh.17568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17568</ArticleId><ArticleId IdType="pmc">PMC8239833</ArticleId><ArticleId IdType="pubmed">34085278</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Mu&#xf1;oz Sandoval D, et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377:eabq1841. doi: 10.1126/science.abq1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. Science. 2021;372:1418&#x2013;23. doi: 10.1126/science.abh1282..</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abh1282.</ArticleId><ArticleId IdType="pmc">PMC8168614</ArticleId><ArticleId IdType="pubmed">33931567</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Gibbons JM, Pade C, Lin KM, Mu&#xf1;oz Sandoval D, Pieper F, et al. Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants. Science. 2022;375:183&#x2013;92. doi: 10.1126/science.abm0811..</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0811.</ArticleId><ArticleId IdType="pmc">PMC10186585</ArticleId><ArticleId IdType="pubmed">34855510</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Swadling L, Gibbons JM, Pade C, Jensen MP, Diniz MO, et al. Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. Sci Immunol. 2020;5:eabf3698. doi: 10.1126/sciimmunol.abf3698.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abf3698</ArticleId><ArticleId IdType="pmc">PMC8101131</ArticleId><ArticleId IdType="pubmed">33361161</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel RR, Painter MM, Lundgreen KA, Apostolidis SA, Baxter AE, Giles JR, et al. Efficient recall of Omicron-reactive B cell memory after a third dose of SARS-CoV-2 mRNA vaccine. Cell. 2022;185:1875&#x2013;87. doi: 10.1016/j.cell.2022.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.04.009</ArticleId><ArticleId IdType="pmc">PMC8989683</ArticleId><ArticleId IdType="pubmed">35523182</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>